News

Nanobodies, megapayoff
Enlarge image

BusinessBelgium

Nanobodies, megapayoff

04.10.2012 - Belgian Ablynx secures €8.5m upfront from Merck Inc. for the development of Nanobodies against two targets, one of them yet unknown.

Camelidae antibody developer Ablynx NV (Ghent) has inked a collaboration with US pharma major Merck & Co. Inc (MSD). The companies collaborate primarily to develop and commercialise Nanobody® candidates directed towards a certain voltage-gated ion channel. Merck also acquired the option to do the same for a second, as yet unknown, target. The deal includes a €6.5m upfront payment and another €2m compensation for research funding. With successfully passed regulatory and commercial milestones in addition to secured royalties, Ablynx will be eligible to receive up to €448 million in total. While Ablynx is in charge of the discovery of the Nanobodies, Merck gains the exclusive global rights to market them and is responsible for research, development, manufacturing and commercialisation of any Nanobody® product resulting from the collaboration. 

After Ablynx showed the proof-of-principle in 2011, things are going well for the company despite the withdrawal of US pharma giant Pfizer almost a year ago. Edwin Moses, Chairman and CEO of Ablynx commented on the new deal: "We are delighted to initiate this collaboration with Merck in the area of ion channels, where to date, monoclonal antibodies have demonstrated little success. Due to the formatting flexibility of Nanobodies, we are able to combine antibody-like selectivity and multi-specificity in one molecule, making them ideal candidates for ion channel modulators." Nanobodies® are a novel class of therapeutic proteins based on single-domain, heavy-chain antibody fragments. They link conventional monoclonal antibody advantages like high specificity with the benefits of small molecule drugs like low sensitivity to temperature and pH changes. So far, Ablynx has approximately 25 programmes in the pipeline, and seven Nanobodies at clinical development stage, including partnerships with pharma and biotech companies like Boehringer Ingelheim (cancer, Alzheimer’s), former Merck Serono (osteoarthritis), Novartis, and Merck & Co.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/nanobodies-megapayoff.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.8%
  • VITA 344.32 EUR7.2%
  • BB BIOTECH157.70 EUR6.1%

FLOP

  • PAION2.24 EUR-27.7%
  • CYTOS0.16 CHF-23.8%
  • MAGFORCE5.90 EUR-16.9%

TOP

  • SANTHERA85.50 CHF2288.3%
  • CO.DON2.75 EUR183.5%
  • PAION2.24 EUR143.5%

FLOP

  • CYTOS0.16 CHF-95.9%
  • 4SC0.97 EUR-44.3%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 24.10.2014